导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.57% | 2995/4773 |
| 近一周 | -1.58% | 2899/5467 |
| 近一月 | -5.35% | 2344/5421 |
| 近一季 | -8.27% | 2632/5238 |
| 近半年 | -3.10% | 2606/4931 |
| 近一年 | -1.48% | 2847/4400 |
| 近两年 | 38.39% | 1956/2954 |
| 近三年 | 20.30% | 1454/2253 |
| 成立以来 | 76.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.61% 3311/4961 |
11.56% 2321/5312 |
- - |
- - |
| 2025 | 17.58% 2368/4813 |
-1.07% 2568/3635 |
1.41% 2345/4076 |
17.40% 2511/4524 |
-0.17% 2398/4813 |
| 2024 | 12.17% 1265/3463 |
2.08% 819/2808 |
-1.53% 1072/3014 |
14.01% 2058/3129 |
-2.13% 1970/3463 |
| 2023 | -10.34% 1290/2656 |
3.47% 1186/2280 |
-4.80% 1291/2385 |
-3.22% 870/2515 |
-5.95% 1569/2655 |
| 2022 | -18.77% 750/2207 |
-13.84% 854/1919 |
5.98% 797/2016 |
-12.03% 631/2113 |
1.14% 1374/2208 |
| 2021 | 7.48% 495/1822 |
-2.53% 663/1255 |
9.82% 520/1330 |
-1.80% 540/1466 |
2.26% 646/1822 |
| 2020 | 38.47% 358/1250 |
-6.91% 514/1028 |
15.50% 494/1067 |
13.38% 323/1164 |
13.59% 348/1184 |
| 2019 | 37.00% 346/1092 |
26.01% 433/739 |
-1.26% 294/788 |
1.76% 360/850 |
8.21% 336/918 |
| 2018 | - - |
- - |
- - |
-0.35% 181/660 |
-11.05% 245/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 平安MSCI中国A股ETF联接A VS. 长安沪深300非周期A(740101) |